Literature DB >> 19699546

CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

Claudia Dittfeld1, Antje Dietrich, Susann Peickert, Sandra Hering, Michael Baumann, Marian Grade, Thomas Ried, Leoni A Kunz-Schughart.   

Abstract

BACKGROUND AND
PURPOSE: CD133 is controversially discussed as putative (surrogate) marker for cancer stem/tumor-initiating cell populations (CSC/TIC) in epithelial tumors including colorectal carcinomas (CRCs). We studied CD133 expression in established CRC cell lines and examined in vitro behavior, radioresponse and in vivo tumor formation of CD133(+/-) subpopulations of one cell line of interest.
MATERIALS AND METHODS: Ten CRC cell lines were analyzed for CD133 expression using flow cytometry and Western blotting. CD133+ and CD133(-) HCT-116 subpopulations were separated by FACS and studied in 2-D and 3-D culture and colony formation assays after irradiation. Subcutaneous xenograft formation was monitored in NMRI (nu/nu) mice. RESULTS AND
CONCLUSIONS: CRC cell lines could be classified into three groups: (i) CD133(-), (ii) CD133+ and (iii) those with two distinct CD133+ and CD133(-) subpopulations. Isolated CD133(+/-) HCT-116 subpopulations were studied relative to the original fraction. No difference was found in 2-D growth, spheroid formation or radioresponse in vitro. Also, tumor formation and growth rate did not differ for the sorted subpopulations. However, a subset of xenografts originated from CD133(-) HCT-116 showed a striking enrichment in the CD133+ fraction. Our data show that CD133 expression is not selective for sphere forming, tumor-initiating or radioresistant subpopulations in the HCT-116 CRC cell lines. This implies that CD133 cannot be regarded as a CSC/TIC marker in all CRC cell lines and that functional measurements of tumor formation have to generally accompany CSC/TIC-directed mechanistic or therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699546     DOI: 10.1016/j.radonc.2009.06.034

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Authors:  Alicia M Mihaliak; Candace A Gilbert; Li Li; Marie-Claire Daou; Richard P Moser; Andrew Reeves; Brent H Cochran; Alonzo H Ross
Journal:  Cancer Lett       Date:  2010-10-28       Impact factor: 8.679

2.  Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Authors:  Ke-li Chen; Feng Pan; Heng Jiang; Jian-fang Chen; Li Pei; Fang-wei Xie; Hou-jie Liang
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

3.  Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Authors:  Thomas W Grunt; Alexandra Hebar; Sylvia Laffer; Renate Wagner; Barbara Peter; Harald Herrmann; Alexandra Graf; Martin Bilban; Martin Posch; Gregor Hoermann; Matthias Mayerhofer; Gregor Eisenwort; Christoph C Zielinski; Edgar Selzer; Peter Valent
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

4.  CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells.

Authors:  Amar Desai; Bryan Webb; Stanton L Gerson
Journal:  Radiother Oncol       Date:  2014-01-16       Impact factor: 6.280

5.  Long-term recovery of irradiated prostate cancer increases cancer stem cells.

Authors:  Yong Mee Cho; Young Seok Kim; Mun Jung Kang; William L Farrar; Elaine M Hurt
Journal:  Prostate       Date:  2012-04-18       Impact factor: 4.104

6.  Genome and transcriptome profiles of CD133-positive colorectal cancer cells.

Authors:  Timo Gaiser; Jordi Camps; Sandra Meinhardt; Danny Wangsa; Quang Tri Nguyen; Sudhir Varma; Claudia Dittfeld; Leoni A Kunz-Schughart; Ralf Kemmerling; Maria R Becker; Kerstin Heselmeyer-Haddad; Thomas Ried
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

7.  Extensive characterization of sphere models established from colorectal cancer cell lines.

Authors:  Ada Collura; Laetitia Marisa; Diletta Trojan; Olivier Buhard; Anaïs Lagrange; Arnaud Saget; Marianne Bombled; Patricia Méchighel; Mira Ayadi; Martine Muleris; Aurélien de Reynies; Magali Svrcek; Jean-François Fléjou; Jean-Claude Florent; Florence Mahuteau-Betzer; Anne-Marie Faussat; Alex Duval
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 8.  At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology.

Authors:  Leo E Gerweck; Hiroaki Wakimoto
Journal:  Cancer Res       Date:  2016-02-15       Impact factor: 12.701

9.  Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.

Authors:  Kumiko Hongo; Shinsuke Kazama; Eiji Sunami; Nelson H Tsuno; Koki Takahashi; Hirokazu Nagawa; Joji Kitayama
Journal:  Med Oncol       Date:  2012-01-14       Impact factor: 3.064

10.  Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620.

Authors:  Chih-Sin Hsu; Chien-Yi Tung; Chih-Yung Yang; Chi-Hung Lin
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.